Loading
Bladder cancer is divided by whether it has grown into the bladder's muscle wall. Before that, it is treated inside the bladder; after, the bladder is usually removed or irradiated.
NMIBC (~75% at diagnosis: Ta, T1, CIS) is managed with TURBT and intravesical therapy, stratified as low, intermediate, or high risk. MIBC (T2-T4) needs radical cystectomy or trimodality bladder preservation, now with perioperative systemic therapy (NIAGARA, EV-303/304). Metastatic disease is treated systemically. Upper-tract urothelial carcinoma (renal pelvis, ureter) shares biology and most drugs.
Showing the technology this term belongs to: Cystoscopy, blue-light imaging & TURBT.
Shares POTOMAC, Intravesical BCG, Bladder & urothelial cancer.
Shares Intravesical BCG, Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Bladder & urothelial cancer.
Shares Cystoscopy, blue-light imaging & TURBT, Intravesical BCG, Bladder & urothelial cancer.
Shares Intravesical BCG, Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Bladder & urothelial cancer.
Shares Radical cystectomy, Organ preservation (watch-and-wait, bladder-sparing, larynx preservation), Bladder & urothelial cancer.
Shares Cystoscopy, blue-light imaging & TURBT, Bladder & urothelial cancer.
Shares Cystoscopy, blue-light imaging & TURBT, Bladder & urothelial cancer.